@article{Panagiotis Baliakas_Theodoros Moysiadis_Anastasia Hadzidimitriou_Aliki Xochelli_Sabine Jeromin_Andreas Agathangelidis_Mattias Mattsson_Lesley-Ann Sutton_Eva Minga_Lydia Scarfò_Davide Rossi_Zadie Davis_Neus Villamor_Helen Parker_Jana Kotaskova_Evangelia Stalika_Karla Plevova_Larry Mansouri_Diego Cortese_Alba Navarro_Julio Delgado_Marta Larrayoz_Emma Young_Achilles Anagnostopoulos_Karin E. Smedby_Gunnar Juliusson_Oonagh Sheehy_Mark Catherwood_Jonathan C. Strefford_Niki Stavroyianni_Chrysoula Belessi_Sarka Pospisilova_David Oscier_Gianluca Gaidano_Elias Campo_Claudia Haferlach_Paolo Ghia_Richard Rosenquist_Kostas Stamatopoulos_2019, place={Pavia, Italy}, title={Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia}, volume={104}, url={https://haematologica.org/article/view/8779}, DOI={10.3324/haematol.2018.195032}, abstractNote={Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides <em>TP53</em> abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides <em>TP53</em> abnormalities, del(11q) and/or <em>SF3B1</em&gt; mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.}, number={2}, journal={Haematologica}, author={Panagiotis Baliakas and Theodoros Moysiadis and Anastasia Hadzidimitriou and Aliki Xochelli and Sabine Jeromin and Andreas Agathangelidis and Mattias Mattsson and Lesley-Ann Sutton and Eva Minga and Lydia Scarfò and Davide Rossi and Zadie Davis and Neus Villamor and Helen Parker and Jana Kotaskova and Evangelia Stalika and Karla Plevova and Larry Mansouri and Diego Cortese and Alba Navarro and Julio Delgado and Marta Larrayoz and Emma Young and Achilles Anagnostopoulos and Karin E. Smedby and Gunnar Juliusson and Oonagh Sheehy and Mark Catherwood and Jonathan C. Strefford and Niki Stavroyianni and Chrysoula Belessi and Sarka Pospisilova and David Oscier and Gianluca Gaidano and Elias Campo and Claudia Haferlach and Paolo Ghia and Richard Rosenquist and Kostas Stamatopoulos}, year={2019}, month={Jan.}, pages={360-369} }